Arrowhead boasts a diversified RNAi pipeline targeting liver, lung, muscle, CNS, and obesity. Read why I recommend buying and ...

Novo Nordisk (NVO) is deeply undervalued after a 43% YTD decline, despite strong fundamentals and global obesity market ...

Looking for cheap 400-hp muscle? Here are 10 used V8 cars that mix serious power with surprising affordability on the used ...

Relmada Therapeutics (RLMD) is a clinical-stage pharma company with no commercialized products and a $141 million market cap.

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of ...

ADVANCED-2 (NCT05951179) is a Phase 2 open-label trial assessing intravesical TARA-002 in NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive ...

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceed ...

Heavy debts rattle investors already twitchy about runaway AI spending Oracle has taken a wallop as tech stocks and bonds ...

Net income from continuing operations of $5.9 million in Q3 2025 Gross margin increased 20.0% sequentially to 49.4% Balance sheet at September 30, 2025, strongest in the Company’s history with $81.5 ...

Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q ...

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

In a recent media Q&A, Honda CEO Toshihiro Mibe said the Trump Administration has pushed back EV adoption by five years.